Cargando…
BRCA1‐like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential
Triple negative (TN) breast cancers make up some 15% of all breast cancers. Approximately 10–15% are mutant for the tumor suppressor, BRCA1. BRCA1 is required for homologous recombination‐mediated DNA repair and deficiency results in genomic instability. BRCA1‐mutated tumors have a specific pattern...
Autores principales: | Severson, Tesa M., Peeters, Justine, Majewski, Ian, Michaut, Magali, Bosma, Astrid, Schouten, Philip C., Chin, Suet-Feung, Pereira, Bernard, Goldgraben, Mae A., Bismeijer, Tycho, Kluin, Roelof J.C., Muris, Jettie J.F., Jirström, Karin, Kerkhoven, Ron M., Wessels, Lodewyk, Caldas, Carlos, Bernards, René, Simon, Iris M., Linn, Sabine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528786/ https://www.ncbi.nlm.nih.gov/pubmed/26004083 http://dx.doi.org/10.1016/j.molonc.2015.04.011 |
Ejemplares similares
-
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
por: Severson, Tesa M., et al.
Publicado: (2017) -
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer
por: Michaut, Magali, et al.
Publicado: (2016) -
Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis
por: Bismeijer, Tycho, et al.
Publicado: (2018) -
A multilevel pan-cancer map links gene mutations to cancer hallmarks
por: Knijnenburg, Theo A., et al.
Publicado: (2015) -
Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
por: Kim, Yongsoo, et al.
Publicado: (2019)